Jaume Pons Sells 20,000 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Free Report) insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.43, for a total value of $168,600.00. Following the completion of the transaction, the insider now directly owns 604,205 shares in the company, valued at $5,093,448.15. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jaume Pons also recently made the following trade(s):

  • On Monday, May 6th, Jaume Pons sold 20,000 shares of ALX Oncology stock. The shares were sold at an average price of $15.92, for a total value of $318,400.00.
  • On Tuesday, April 16th, Jaume Pons sold 50,000 shares of ALX Oncology stock. The stock was sold at an average price of $14.20, for a total value of $710,000.00.
  • On Thursday, April 4th, Jaume Pons sold 20,000 shares of ALX Oncology stock. The shares were sold at an average price of $11.15, for a total value of $223,000.00.

ALX Oncology Stock Down 2.9 %

Shares of ALX Oncology stock opened at $9.01 on Friday. ALX Oncology Holdings Inc. has a 1 year low of $3.94 and a 1 year high of $17.83. The business has a 50-day moving average of $13.74 and a two-hundred day moving average of $13.44. The company has a market capitalization of $469.42 million, a P/E ratio of -2.42 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.21 and a quick ratio of 5.21.

ALX Oncology (NASDAQ:ALXOGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.16. As a group, equities analysts predict that ALX Oncology Holdings Inc. will post -2.89 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. abrdn plc acquired a new position in shares of ALX Oncology during the fourth quarter worth about $986,000. China Universal Asset Management Co. Ltd. boosted its position in shares of ALX Oncology by 445.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after buying an additional 4,706 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in ALX Oncology during the fourth quarter valued at approximately $28,000. Hsbc Holdings PLC acquired a new position in ALX Oncology during the third quarter valued at approximately $168,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in ALX Oncology during the fourth quarter valued at approximately $215,000. 97.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on ALXO. Stifel Nicolaus reissued a “hold” rating and issued a $14.00 price objective (up previously from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of ALX Oncology in a report on Wednesday, April 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Wednesday, May 29th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, ALX Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $18.83.

View Our Latest Analysis on ALXO

About ALX Oncology

(Get Free Report)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

Recommended Stories

Insider Buying and Selling by Quarter for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.